Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

No abstract

In a wide variety of habitats, including some heavily urbanised areas, the adaptability of populations of common bottlenose dolphin (Tursiops truncatus) may depend on the social structure dynamics. Nonetheless, the way in which these adaptations take place is still poorly understood. In the present study we applied photo-identification techniques to investigate the social structure of the common bottlenose dolphin population inhabiting the Gulf of Alghero (Sardinia, Italy), analysing data recorded from 2008 to 2019. The social structure analysis showed a division of the entire population into five different communities and the presence of non-random associations, while there was no evidence of segregation between sexes. Furthermore, results highlighted an important change in social structure through time, likely due to a reduction in fish farm activity since 2015. The division of the population into different communities, the presence of segregation based on the foraging strategy (inside or outside the fish farm area) and the social network measures were evaluated by analysing independently the two datasets: the intense and low farm activity periods: 2008–2014 and 2015–2020, respectively. Segregation among individuals belonging to the same foraging strategy class was found only in the earlier period, and the composition of the four communities was consistent with this result. Our study improves the knowledge about bottlenose dolphin adaptation, as a lower complexity in social structure was linked to a reduction in anthropogenic food availability.

Interferon β (INFβ) and glatiramer acetate (GA) are widely used in patients with relapsing-remitting multiple sclerosis (RRMS). However, it is still unclear whether they have different efficacy. We performed a systematic search of head-to-head trials for gaining objective reliable data to compare the two drugs, using the Cochrane Collaboration methodology. We identified five randomised-controlled trials (RCTs) (2858 participants) comparing directly INFβ versus GA in RRMS. All studies were at high risk for attrition bias. Both therapies showed similar efficacy at 24 months, considering clinical (patients with relapse or progression) and one MRI activity (enhancing lesions) measure. At 3 years, evidence from a single study showed that the relapse rate was higher in the INFβ group than in the GA group (risk ratio 1.40, 95% CI 1.13 to 1.74, p 0.002). However, the average reduction in T2-weighted and T1-weighted lesion volume was significantly greater in the INFβ group than in the GA group (mean difference (MD) -0.58, 95% CI -0.99 to -0.18, p 0.004, and MD -0.20, 95% CI -0.33 to -0.07, p 0.003, respectively). The number of participants who dropped out of the studies because of adverse events was similar in the two groups. These data support clinicians in the use of these therapies, based on their similar safety and efficacy in the prevention of disease activity, although the different effect on MRI measures and the different tolerability might have a role in the therapeutic choice at the individual level.

No abstract